1995
DOI: 10.1007/bf00176772
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacological characterization of muscarinic acetylcholine binding sites in human and bovine cerebral microvessels

Abstract: The aim of this study was to investigate the presence of muscarinic receptors in human brain microvessels (MVs) and capillaries (CAPs) and, further, to pharmacologically characterize these receptors as well as those in bovine cerebral microvascular beds. For this purpose, the binding of [3H]N-methyl scopolamine ([3H]NMS) was assessed in isolated human and bovine cerebral MVs and CAPs and competition studies were performed against [3H]NMS binding with several well characterized muscarinic antagonists. The antag… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
15
1

Year Published

1997
1997
2008
2008

Publication Types

Select...
4
1
1

Relationship

1
5

Authors

Journals

citations
Cited by 26 publications
(17 citation statements)
references
References 42 publications
1
15
1
Order By: Relevance
“…The exclusive mRNA expression of the m2 subtype and the ability of the mAChR antagonist AF-DX 384 (Dorje et aI.,199 1) to block the inhibitory effect of car bachol on cAMP production (the downstream effect of m2 activation) unequivocally indicated the existence of functional endothelial m2 mAChR. The apparent dis-crepancy between the present results and the inability of previous radioligand binding studies to detect m2 mAChR in isolated human cerebral microvasculature (Linville and Hamel, 1995) could possibly be explained by the fact that radioligand binding studies, unlike PCR, require that a sizable amount of the receptor protein be present to be detectable. In fact, from the present results, m2 receptors are located in the endothelial but not in the muscular compartment (see below) of the intraparenchy mal vascular tissue.…”
Section: Discussioncontrasting
confidence: 46%
See 4 more Smart Citations
“…The exclusive mRNA expression of the m2 subtype and the ability of the mAChR antagonist AF-DX 384 (Dorje et aI.,199 1) to block the inhibitory effect of car bachol on cAMP production (the downstream effect of m2 activation) unequivocally indicated the existence of functional endothelial m2 mAChR. The apparent dis-crepancy between the present results and the inability of previous radioligand binding studies to detect m2 mAChR in isolated human cerebral microvasculature (Linville and Hamel, 1995) could possibly be explained by the fact that radioligand binding studies, unlike PCR, require that a sizable amount of the receptor protein be present to be detectable. In fact, from the present results, m2 receptors are located in the endothelial but not in the muscular compartment (see below) of the intraparenchy mal vascular tissue.…”
Section: Discussioncontrasting
confidence: 46%
“…Al though more than one population of mAChR were later suggested (Garda-Villalon et al, 199 1; Linville and Hamel, 1995), there was disagreement as to which mAChR SUbtypes were present in the brain microvascu lature. Garda-Villalon and colleagues exclusively iden tified a pharmacologic m4 mAChR in bovine microvas cular fractions, but others concluded on the basis of phar macologic characterization and correlation analyses with the cloned mAChR that the ml, m3, and possibly the m5 receptors were most likely the cerebromicrovascular re ceptors present, not only in bovine, but also in human cerebromicrovascular fractions (Linville and Hamel, 1995). In the present study, the high sensitivity and se lectivity of the RT-PCR approach, together with the demonstration of functional second messenger signaling pathways in the cell cultures, provided unequivocal sup port for the presence of cerebromicrovascular m 1, m3, and m5 mAChR, and further allowed us to identify en dothelial m2 mAChR.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations